Literature DB >> 15505495

Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells.

Hong Wang1, Jawahar L Mehta, Kui Chen, Xingjiang Zhang, Dayuan Li.   

Abstract

OBJECTIVES: Human urotensin II (hU-II) is a cyclic peptide highly expressed in cardiac tissues and blood vessels. hU-II is a potent vasoconstrictor. Recent studies indicate that urotensin II participates in myocardial remodeling after injury. This study was designed to study the role of hU-II in the expression of matrix metalloproteinase-1 (MMP-1) and collagen-1 in human umbilical vein endothelial cells (HUVECs) and underlying intracellular signaling mechanisms. METHODS AND
RESULTS: Cultured HUVECs were incubated with hU-II (10 to 80 nM) for 3 to 24 hours. hU-II increased the expression (mRNA and protein) of collagen-1 in a concentration- and time-dependent manner. In contrast, hU-II decreased the expression and activity of MMP-1. Further, hU-II caused the phosphorylation of mitogen-activated protein kinase p42/44 (MAPKp42/44). This effect of hU-II was inhibited by pretreatment of cells with the MEK inhibitor (PD98059, 10 microM). In addition, treatment of cells with PD98059 attenuated protein expression of collagen-1 and MMP-1 elicited by hU-II (P < 0.01 versus hU-II alone).
CONCLUSIONS: Our observations provide evidence that hU-II modulates the expression of MMP-1 and collagen-1 in HUVECs, and MAPKp42/44 activation may play a signal transduction role in this process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505495     DOI: 10.1097/00005344-200411000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

2.  The efficiency of a urotensin II antagonist in an experimental lung fibrosis model.

Authors:  Ahmet Mesut Onat; Ibrahim Halil Turkbeyler; Yavuz Pehlivan; Tuncer Demir; Davut Sinan Kaplan; Seyithan Taysi; Ali Osman Ceribasi; Ediz Tutar; Bunyamin Kisacik
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 3.  Urotensin-II and cardiovascular diseases.

Authors:  Nicolas Bousette; Adel Giaid
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

4.  Effectiveness of palosuran in bleomycin-induced experimental scleroderma.

Authors:  Tuncer Demir; Ibrahim Turkbeyler; Davut Sinan Kaplan; Yavuz Pehlivan; Mustafa Orkmez; Ediz Tutar; Seyithan Taysi; Bunyamin Kisacik; Ahmet Mesut Onat; Cahit Bagcı
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

5.  NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II.

Authors:  Isabel Diebold; Andreas Petry; Maximilian Burger; John Hess; Agnes Görlach
Journal:  Mol Biol Cell       Date:  2011-09-30       Impact factor: 4.138

6.  Upregulation of cGMP-dependent Protein Kinase (PRKG1) in the Development of Adolescent Idiopathic Scoliosis.

Authors:  Cang-Long Hou; Bo Li; Ya-Jun Cheng; Ming Li; Zong-de Yang
Journal:  Orthop Surg       Date:  2020-06-18       Impact factor: 2.071

7.  Urotensin-II Immunoreactivity in Normolipidemic and Hyperlipidemic New Zealand White Rabbits Following Balloon Angioplasty and Stenting.

Authors:  Nicolas Bousette; Fazila Chouiali; Eliot H Ohlstein; Stephen A Douglas; Adel Giaid
Journal:  Int J Biomed Sci       Date:  2007-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.